Incanthera PLC - Filing of Trademark Applications
RNS Number : 9849M
Incanthera PLC
27 September 2021
 

 

 

27 September 2021

 

Incanthera plc

 

("Incanthera" or the "Company")

 

Filing of Trademark Applications for Commercial Skin Cancer Product 

 

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, is pleased to announce the filing of two trademark names for the commercial use of its skin cancer formulation, currently identified as Sol.

 

The Company filed UK trademark applications, to register the signs ACTINOMOD and ACTINODERM on 22 and 21 September 2021 respectively.  The applications were given application numbers UK00003699147 and UK00003698302 respectively.  The applications will now be examined by the UK trade marks office (UKIPO).

 

These filings are in line with the ongoing progression of Incanthera's commercialisation goals for its innovative skin cancer technology formulation.

 

The Company continues to positively progress discussions with two prioritised global companies for the potential license of its formulation for the treatment of actinic keratosis and prevention of skin cancer.

 

 Tim McCarthy, Chairman said:  

 

"As our licencing discussions progress, the filing of these two trademark names will allow us to look at various branding and marketing opportunities in readiness for next steps.

 

We continue to make good progress in discussions with our two prioritised partners."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

 

The directors of the Company take responsibility for this announcement.

 

For further enquiries:

 

Incanthera plc

www.incanthera.com

 

Tim McCarthy, Chairman

tim.mccarthy@incanthera.com

 

Simon Ward, Chief Executive Officer

simon.ward@incanthera.com

 

Suzanne Brocks, Head of Communications

suzanne.brocks@incanthera.com

 

 

 

+44 (0) 7831 675747

 

 

+44 (0) 7747 625506

 

 

+44 (0) 7776 234600



Aquis Exchange Corporate Adviser: 

Cairn Financial Advisers LLP

Jo Turner/James Lewis

+44 (0) 20 7213 0880



Broker

Stanford Capital Partners Ltd

Patrick Claridge/John Howes/Bob Pountney

                              + 44 (0) 203 650 3650

 

 


                         

Notes to Editors

 

Incanthera is a specialist oncology company focused on innovative technologies in oncology and dermatology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

 

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions. 

 

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

 

For more information on the Company please visit: www.incanthera.com

 

@incantheraplc

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXFZGZLGVRGMZZ ]]>